Sound Pharma to Present at Upcoming Life Science Investor Conferences
Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at four upcoming life science and healthcare investor conferences over the next month.
24 th Annual Needham Healthcare Conference on April 9-10
25 th Life Sciences Innovation Northwest on April 23-24
Citibank Biotech Private Access Investor Day on April 24
Morgan Stanley Inaugural Private Company & Investor Day on May 5
Dr. Jonathan Kil, Co-Founder and CEO will provide an update on SPI-1005, the novel oral anti-inflammatory, the first investigational drug to achieve its co-primary endpoints in a pivotal Phase 3 randomized double blinded placebo-controlled trial (RCTs) to treat Meniere's disease (STOPMD-3). There are no FDA approved drugs for the treatment of hearing loss, tinnitus, dizziness or vertigo, the primary symptoms of MD. SPI-1005 has achieved positive safety and efficacy results in five different RCTs involving MD, acute noise-induced hearing loss, and aminoglycoside-induced ototoxicity.
About SPI-1005
SPI-1005 is an investigational new drug that contains ebselen, a new chemical entity that mimics and induces glutathione peroxidase (GPx) activity. GPx1 is a critical enzyme that repairs injured and dying cells in the inner ear, retina, prefrontal cortex of brain, lung, and kidney, and is often reduced during and after exposure to environmental insults or aging. Consequently, neuroinflammation can progress throughout the peripheral and central nervous system leading to neurodegeneration. SPI-1005 is being developed for several neurotologic indications including Meniere's disease (hearing loss, tinnitus, intermittent dizziness, and episodic vertigo), noise-induced hearing loss (including tinnitus) and two types of ototoxicity (hearing loss, tinnitus, dizziness, or vertigo) caused by aminoglycoside antibiotics (such as tobramycin or amikacin) or platinum-based chemotherapy (such as cisplatin or carboplatin). To date, no significant drug-drug interactions have been observed across multiple study populations including Meniere's disease, and patients with cystic fibrosis, bipolar mania, and treatment-resistant depression. Thirteen SPI-1005 trials have been completed treating 790 patients with 400+ more anticipated later this year.
About Sound Pharmaceuticals
Sound Pharma is a private biotechnology company studying SPI-1005 under six active Investigational New Drug Applications involving several neurotologic indications including the prevention and treatment of aminoglycoside-induced ototoxicity co-funded by the Cystic Fibrosis Foundation and hearing preservation in cochlear implant patients co-funded by MED-EL. Details of the SPI-1005 clinical trials can be viewed online at www.clinicaltrials.gov or www.soundpharma.com. Please contact [email protected] for further information.
SOURCE: Sound Pharmaceuticals
Copyright Business Wire 2025.
PUB: 04/08/2025 09:10 AM/DISC: 04/08/2025 09:10 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
CUPE: Liberals reward Air Canada's refusal to bargain fairly by crushing flight attendants' Charter rights
TORONTO--(BUSINESS WIRE)--Air Canada asked the government to crush underpaid flight attendants' Charter rights, and Jobs Minister Patty Hajdu only waited a few hours to deliver. The Liberal government has invoked Section 107 of the Canada Labour Code to end a strike by Air Canada flight attendants fighting to end unpaid work and poverty wages. "The Liberals have talked out of both sides of their mouths. They said the best place for this is at the bargaining table. They refused to correct this historic injustice through legislation," said Wesley Lesosky, President of the Air Canada Component of CUPE. "Now, when we're at the bargaining table with an obstinate employer, the Liberals are violating our Charter rights to take job action and give Air Canada exactly what they want — hours and hours of unpaid labour from underpaid flight attendants, while the company pulls in sky-high profits and extraordinary executive compensation." CUPE came to the table with data-driven and reasonable proposals for a fair cost-of-living wage increase and an end to forced unpaid labour. Air Canada responded by sandbagging the negotiations. The Liberal government is rewarding Air Canada's refusal to negotiate fairly by giving them exactly what they wanted. This sets a terrible precedent. Contrary to the Minister's remarks, this will not ensure labour peace at Air Canada. This will only ensure that the unresolved issues will continue to worsen by kicking them down the road. Nor will it ensure labour peace in this industry — because unpaid work is an unfair practice that pervades nearly the entire airline sector, and will continue to arise in negotiations between flight attendants and other carriers.
Business Wire
2 hours ago
- Business Wire
'This government is anti-union and anti-worker': CUPE NS Denounces Use of Bill 107
HALIFAX, Nova Scotia--(BUSINESS WIRE)--CUPE Nova Scotia strongly condemns the federal government's decision to interfere in workers' right to collective bargaining and job action by invoking Section 107 of the Canada Labour Code. 'Clearly, this government is anti-union and anti-worker,' said Alan Linkletter, CUPE Nova Scotia President. 'Forcing workers back on the job instead of supporting free and fair collective negotiations directly contradictions workers' rights that are guaranteed under the Canadian Charter of Rights and Freedoms.' Air Canada has asked the government to crush striking workers' Charter rights, and Federal Labour minister Patty Hajdu is ready to deliver. Hajdu announced that the federal government will be invoking Section 107 at a press conference this afternoon, citing the financial welfare of Canadians and the economy at large as a deciding factor for this decision. 'She says this move is for the financial security of Canadians—are these workers not Canadians? Does their welfare not matter? How can you be financially secure when you don't even get paid for all of the hours you work?' Contrary to the Minister's remarks, this will not ensure labour peace in Canada. This will only push this fight onto the next group of workers in negotiations, while Air Canda's flight attendants continue to work for a billion-dollar company for free. Flight attendants are only paid when the plane is moving, and work as many as 35 unpaid hours a month performing vital duties that ensure the safe and smooth operation of each flight. Now, instead of paying flight attendants for all the hours they work, Air Canada has clearly sought help from the federal government to continue exploiting their employees. 'Minister Hajdu's comments indicate a clear lack of respect for workers' rights,' said Sherry Hillier, President of CUPE Newfoundland and Labrador and National General Vice President for Atlantic Canada. 'By using Section 107 to force workers back on the job yet again, they're setting a pattern. And that pattern is that Liberals don't care about Canadians.' Recent polling data indicates that 9 out of 10 Canadians support Air Canada flight attendants' fight for fair pay. 88% per cent of Canadians believe flight attendants should be paid for all work-related duties including boarding, delays, and safety checks. 76% support raising their pay to reflect the important safety role they play. 59% believe the federal government should respect flight attendants' right to take job action–even if it causes travel disruptions. CUPE represents over 10,000 Air Canada flight attendants across the country, and workers have been demonstrating at Halifax Stanfield International Airport since 6AM. 'Messages of support have been pouring in for these workers from across the country,' continued Linkletter. 'Canadians stand with us. Our elected representatives should, too.'
Business Insider
14 hours ago
- Business Insider
Why Morgan Stanley Increased Its Apple (AAPL) iPhone Production Estimate
Investment firm Morgan Stanley (MS) recently increased its estimate for Apple's (AAPL) iPhone production in the September quarter by 8%. Indeed, it is now forecasting 54 million units instead of 50 million for the tech giant. This change is due to stronger-than-expected iPhone sales in the June quarter, which brought inventory levels below normal and opened up more room for restocking. Analysts led by Erik Woodring highlighted that the increased production is focused entirely on the upcoming iPhone 16 and iPhone 16 Pro Max, with each contributing an extra 2 million units. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Interestingly, the team at Morgan Stanley is becoming more optimistic about Apple overall. In fact, it believes that many of the same positive trends from last year are still in place, such as longer iPhone upgrade cycles, strong demand buildup, and new product designs in the pipeline. It also notes that the peak risks from tariffs have likely passed. Additionally, Apple hasn't raised prices for its Services segment in two years, which is something the analysts view as an underused strategy that could drive future growth. As a result, they believe that earnings estimates are likely to trend higher, which historically has led to rallies for Apple stock. Looking further ahead, the analysts kept their iPhone 17 production forecast unchanged at 80 to 85 million units for the second half of Calendar Year 2025. This range is slightly below or roughly in line with the 84 million new-model iPhones produced in the second half of 2024. They also noted that iPhone production in the December quarter tends to be more volatile than in the September quarter. Indeed, excluding the COVID years (2020 and 2021), December builds have fluctuated from 35% to 71% higher than the previous quarter. Is Apple a Buy or Sell Right Now? Turning to Wall Street, analysts have a Moderate Buy consensus rating on AAPL stock based on 16 Buys, 11 Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average AAPL price target of $239.18 per share implies 3.5% upside potential.
